GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

NewsGuard 100/100 Score

GlaxoSmithKline Inc. (GSK) As part of its broad commitment to improving access to medicines and its ongoing support for Canada's Access to Medicines Regime (CAMR), GlaxoSmithKline confirms it will not object - through CAMR - to allow Canadian company (Apotex) to continue manufacturing their drug for the treatment of HIV/AIDS in Rwanda. Apotex currently manufactures a fixed dose combination (FDC) antiretroviral (ARV), containing two molecules over which GSK has patent rights (zidovudine and lamivudine).

GSK believes that CAMR is simple, straightforward and efficient. It enables the government to authorise the production of certain patented medicines for export, and includes controls which are designed to ensure that these essential medicines reach the intended patients. At the time of the previous request, it took only 26 days for GSK to give its consent to Apotex to manufacture FDC.

On expiry of an authorization granted by the Commissioner of Patents, should the product still be required by the importing country, the Commissioner of Patents may grant a new authorization. GSK reconfirmed that if Apotex makes a new application to the Commissioner of Patents which meets CAMR's requirements, GSK will not object to Apotex supplying Rwanda with FDCs containing two GSK HIV molecules. This is reflective of GSK's support for the humanitarian goals of CAMR.

Canadian generic firm Apotex was first granted authorization to export the FDC containing two GSK patented molecules by the Commissioner of Patents on September 19, 2007, two months following Rwanda's request for assistance. This further demonstrates that in its current form CAMR operates effectively and efficiently.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service